secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2024-02-09T23:59:59+00:00
Accession:  0001654954-24-001539
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech reports Q1 net loss of $1.7M; secures up to C$23M govt funding for ARDS drug
--------------------------------------------------------------------------------

- Net loss $1.7M ($0.54/share) vs $2.3M ($0.89) YoY; operating expenses down to $1.9M from $2.4M.
- Cash and equivalents $4.3M at Dec 31, 2023; working capital $3.4M.
- Secured up to C$23M from Canadian government for EB05 ARDS Phase 3; regulators approved harmonized US/Canada trial.
- Planning Phase 2 for vitiligo (anti-CXCL10 mAb) and pulmonary fibrosis (EB05); seeking partnerships for dermatitis candidate EB01.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/0001654954-24-001539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495424001539/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-001539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer